Could rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs

Could rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs

Summary: Multiple sclerosis (MS) is a leading cause of neurological disability in young adults, affecting an estimated 2.8 million people worldwide. Early treatment with high-efficacy therapies is associated with better long-term outcomes, yet access to these therapies remains limited in many countr...

Full description

Saved in:
Bibliographic Details
Main Authors: Guilherme Diogo Silva, Leonardo Zumerkorn Pipek, Mateus Boaventura de Oliveira, Samira Luisa Apóstolos-Pereira, Tarso Adoni, Angelina Maria Martins Lino, Dagoberto Callegaro, Luiz Henrique Martins Castro
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:The Lancet Regional Health. Americas
Subjects:
Multiple sclerosis
Rituximab
Relapses
Cost
Public health
Online Access:http://www.sciencedirect.com/science/article/pii/S2667193X25001814
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2667193X25001814

Similar Items